ArticleBlood advances2025

Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study.

Eugenio Galli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.